The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs seen on nocamels.com.
Israeli and US medtech companies have teamed up to create a program that uses artificial intelligence to identify patients at high risk for respiratory or pulmonary diseases such as lung cancer.
The LungFlag AlgoMarker, which analyzes data from a patient’s electronic health record, is a collaboration between Medial EarlySign (opens in a new tab), a Hod Hasharon-based company that develops clinical predictive analytics, and Geisinger (opens in a new tab), an integrated healthcare system from Pennsylvania.
Working with Geisinger, Medial EarlySign developed the program to facilitate earlier invention, which is a key feature of the American healthcare provider’s care model as it helps improve clinical outcomes, creates higher patient satisfaction and reduces medical costs.
Medial EarlySign is an Israeli clinical predictive analytics company. Medial EarlySign COO, CFO, and Chief Commercial Officer EU Itai Katzir is a Technion alumnus.